Opportunity Information: Apply for PA 11 074
Apply for PA 11 074
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research 93.399 Cancer Control.
- This funding opportunity was created on Dec 9, 2010 and posted on Dec 9, 2010.
- Applicants must submit their applications by Jan 7, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal governments (Federally recognized) City or township governments Special district governments For profit organizations other than small businesses Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The opportunity titled "Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21)" (Funding Opportunity Number PA 11-074) was a National Cancer Institute (NCI), National Institutes of Health (NIH) funding announcement focused on early-stage, exploratory projects that connect mitochondrial biology to practical cancer biomarker development. Its central goal was to stimulate new research ideas and proof-of-concept studies that could lead to mitochondrial-related biomarkers useful across the cancer control spectrum, including early detection, diagnostic classification, prognosis prediction, cancer risk assessment, and monitoring response to preventive or symptom-improving (ameliorative) interventions. In other words, the FOA was aimed at moving mitochondrial signals from basic observations toward measurable indicators that could meaningfully inform clinical or population-level cancer decisions.
This was an NIH Exploratory/Developmental Grant mechanism (R21), which typically supports high-impact, higher-risk concepts and early validation work rather than large, long-term programs. Projects under this FOA were expected to focus on developing and validating new biomarkers specifically tied to mitochondria, such as measures reflecting mitochondrial DNA (mtDNA) alterations, mitochondrial dysfunction, oxidative phosphorylation changes, mitochondrial metabolism, reactive oxygen species-related signatures, mitochondrial copy number, mitochondrial gene expression, or other mitochondrial-linked molecular or functional readouts. The emphasis on "develop and validate" signals that applications were expected not just to propose a biomarker concept, but to take tangible steps toward showing it can be measured reliably and linked credibly to cancer endpoints like detection, diagnosis, prognosis, risk, or treatment/prevention response.
From an organizational standpoint, the program sat within NIH's cancer mission areas and mapped onto several CFDA program categories, including cancer cause and prevention research (93.393), cancer detection and diagnosis research (93.394), cancer treatment research (93.395), cancer biology research (93.396), and cancer control (93.399). That breadth reflects how mitochondrial biomarkers can be relevant in multiple settings: understanding risk and etiology in epidemiology studies, improving screening or early detection strategies, refining diagnostic and prognostic models, and tracking how patients respond biologically to interventions intended to prevent cancer, slow progression, or reduce harm.
The award structure listed an award ceiling of $200,000, and there was no cost sharing or matching requirement. Practically, that meant applicants were not required to bring additional non-federal funds to secure the award, which often lowers barriers for smaller organizations or early-stage teams to participate. The funding instrument was a discretionary grant, consistent with standard NIH competitive grantmaking.
Eligibility was broad and inclusive, covering a wide range of potential applicants. Eligible entities included public and state-controlled institutions of higher education and private institutions of higher education, nonprofits with and without 501(c)(3) status, for-profit organizations other than small businesses, and small businesses as well. Governmental applicants could include state governments, county governments, and city or township governments, plus special district governments and public housing authorities/Indian housing authorities. The FOA also explicitly included Native American tribal governments (federally recognized), tribal organizations that are not federally recognized tribal governments, and tribally controlled colleges and universities (TCCUs). It extended eligibility to various mission-serving institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. Importantly, it also allowed non-domestic (non-U.S.) entities (foreign organizations), regional organizations, U.S. territories or possessions, and eligible federal agencies, which signaled an openness to international or multi-regional biomarker development efforts where unique cohorts, biospecimens, or technical capabilities might exist.
Timing details show that the FOA was posted and created on December 9, 2010, with an original and current closing date of January 7, 2014, and it was archived on February 7, 2014. That means it was an active opportunity for multiple submission cycles during that window, after which it was formally closed and moved to archive status, which is typical for older NIH program announcements that are later replaced, reissued, or folded into newer solicitations.
For applicants and stakeholders who needed official details, NIH provided an additional information link to the full announcement hosted on the NIH grants website (http://grants.nih.gov/grants/guide/pa-files/PA-11-074.html). For access or technical issues, the contact route provided was the NIH Office of Extramural Research (OER) webmaster (FBOWebmaster@OD.NIH.GOV), which is consistent with NIH practice for resolving problems reaching FOA documentation online.
Overall, this FOA was essentially a targeted call for innovative, early-stage biomarker work where mitochondria are not just a background biological feature but the centerpiece of the measurement strategy. The intended payoff was to broaden and strengthen the pipeline of mitochondrial-based indicators that could eventually improve how cancer is detected earlier, categorized more accurately, predicted in terms of outcomes, assessed for risk in populations, or monitored for response to interventions aimed at prevention or reducing disease burden.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The opportunity is titled "Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R21)" and the Funding Opportunity Number is PA 11-074.
Which agency offered this funding opportunity?
This funding announcement was offered by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH).
What was the overall purpose of this funding opportunity?
The central purpose was to stimulate early-stage, exploratory research that connects mitochondrial biology to practical cancer biomarker development, with proof-of-concept work intended to move mitochondrial signals toward measurable indicators that can inform cancer decisions.
What types of projects was the FOA trying to encourage?
It encouraged new research ideas and proof-of-concept studies focused on developing and validating biomarkers specifically tied to mitochondria, with clear relevance to cancer endpoints and cancer control use cases.
What does the "R21" mechanism mean in this announcement?
R21 refers to the NIH Exploratory/Developmental Grant mechanism, which typically supports early, higher-risk, high-impact concepts and initial validation work rather than large, long-term research programs.
What is meant by "develop and validate" in the context of this FOA?
Based on the description, applications were expected to go beyond proposing a biomarker concept by taking tangible steps to show the biomarker can be measured reliably and can be linked credibly to cancer-related endpoints such as detection, diagnosis, prognosis, risk, or response to interventions.
What kinds of mitochondrial biomarkers were specifically within scope?
Examples listed in the announcement included biomarkers reflecting mitochondrial DNA (mtDNA) alterations, mitochondrial dysfunction, oxidative phosphorylation changes, mitochondrial metabolism, reactive oxygen species-related signatures, mitochondrial copy number, mitochondrial gene expression, and other mitochondrial-linked molecular or functional readouts.
What cancer-related uses were these biomarkers intended to support?
The FOA emphasized biomarkers that could be useful across the cancer control spectrum, including early detection, diagnostic classification, prognosis prediction, cancer risk assessment, and monitoring response to preventive or symptom-improving (ameliorative) interventions.
Was this FOA focused more on basic mitochondrial biology or on practical measurement tools?
It was positioned as a bridge from basic observations to practical biomarker development, emphasizing measurable indicators that could meaningfully inform clinical or population-level cancer decisions.
How broad was the program scope within NIH cancer mission areas?
The announcement mapped to multiple NIH cancer mission categories, reflecting broad relevance of mitochondrial biomarkers to etiology and prevention, detection and diagnosis, treatment research, cancer biology, and cancer control.
Which CFDA program categories were associated with this FOA?
The FOA was associated with several CFDA categories: 93.393 (cancer cause and prevention research), 93.394 (cancer detection and diagnosis research), 93.395 (cancer treatment research), 93.396 (cancer biology research), and 93.399 (cancer control).
What was the maximum award amount listed for this opportunity?
The award ceiling listed for this FOA was $200,000.
Was cost sharing or matching required?
No. The opportunity stated there was no cost sharing or matching requirement.
What type of funding instrument was used?
The funding instrument was a discretionary grant, consistent with standard NIH competitive grantmaking.
Who was eligible to apply?
Eligibility was described as broad and inclusive, spanning academic institutions, nonprofit and for-profit organizations, small businesses, multiple levels of government, tribal entities, and other eligible organizations listed in the announcement.
Were colleges and universities eligible?
Yes. Eligible entities included public and state-controlled institutions of higher education and private institutions of higher education.
Could nonprofit organizations apply?
Yes. Nonprofits with and without 501(c)(3) status were included as eligible applicants.
Could for-profit organizations apply?
Yes. For-profit organizations other than small businesses were eligible, and small businesses were also eligible.
Could government entities apply?
Yes. Eligible governmental applicants included state governments, county governments, and city or township governments, as well as special district governments and public housing authorities/Indian housing authorities.
Were tribal governments and tribal organizations eligible?
Yes. The FOA included Native American tribal governments (federally recognized), tribal organizations that are not federally recognized tribal governments, and tribally controlled colleges and universities (TCCUs).
Did the FOA encourage participation by mission-serving institutions?
It explicitly included institutions and organizations such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.
Were foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA allowed non-domestic (non-U.S.) entities (foreign organizations), as well as regional organizations, U.S. territories or possessions, and eligible federal agencies.
When was this funding opportunity posted and when did it close?
The FOA was posted and created on December 9, 2010. The original and current closing date listed was January 7, 2014.
What does it mean that the FOA was archived?
It was archived on February 7, 2014, indicating it was formally closed and moved to archive status after its active period.
Where could applicants find the full official announcement text?
The announcement provided an NIH grants website link for the full details: http://grants.nih.gov/grants/guide/pa-files/PA-11-074.html
Who was listed as a contact for access or technical issues with the FOA webpage?
The contact route provided for access or technical issues was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the main takeaway about what this FOA was trying to achieve?
It was a targeted call for innovative, early-stage biomarker work where mitochondria were the centerpiece of the measurement strategy, with the intended payoff of strengthening the pipeline of mitochondrial-based indicators to improve cancer detection, classification, outcome prediction, risk assessment, or monitoring response to interventions.
Browse more opportunities from the same category: Education Health
Next opportunity: WaterSMART Water and Energy Efficiency Grants for FY 2011
Previous opportunity: Mitochondria in Cancer Epidemiology, Detection, Diagnosis and Prognosis (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 11 074
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 11 074) also looked into and applied for these:
| Funding Opportunity |
|---|
| Cancer Prevention Research Small Grant Program (R03) Apply for PAR 11 079 Funding Number: PAR 11 079 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Shared Instrumentation Grant Program (S10) Apply for PAR 11 081 Funding Number: PAR 11 081 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 11 084 Funding Number: PAR 11 084 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| New Molecular Entities to Treat Substance Use Disorders (R01) Apply for RFA DA 12 001 Funding Number: RFA DA 12 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploring Human Induced Pluripotent Stem Cells for Substance Abuse Research (R21) Apply for RFA DA 11 012 Funding Number: RFA DA 11 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01) Apply for RFA NR 11 003 Funding Number: RFA NR 11 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21) Apply for RFA NR 11 004 Funding Number: RFA NR 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Acute Life Threatening Conditions and Opportunities for Palliative and End of Life Care Research (R01) Apply for RFA NR 11 008 Funding Number: RFA NR 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Interdisciplinary Approaches for HIV/AIDS Risk Avoidance Decision Making in Developing Adolescents (R01) Apply for RFA NR 11 007 Funding Number: RFA NR 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Alzheimers Disease Pilot Clinical Trials (R01) Apply for PAR 11 100 Funding Number: PAR 11 100 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| U.S. India Bilateral Brain Research Collaborative Partnerships (U.S. India BRCP) (R21) Apply for PAR 11 099 Funding Number: PAR 11 099 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Increasing Opportunities in Advanced Heart Failure and Palliative Care Research (R01) Apply for RFA NR 11 006 Funding Number: RFA NR 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Reducing Health Disparities Among Minority and Underserved Children (R01) Apply for PA 11 104 Funding Number: PA 11 104 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Reducing Health Disparities Among Minority and Underserved Children (R21) Apply for PA 11 105 Funding Number: PA 11 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Lasker Clinical Research Scholars Program (SI2) Apply for RFA OD 11 001 Funding Number: RFA OD 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pre Application for the 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 11 102 Funding Number: PAR 11 102 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 11 009 Funding Number: RFA DA 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 11 002 Funding Number: RFA CA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Predictive Animal Models for Smoking Cessation Medications (U54) Apply for RFA DA 11 014 Funding Number: RFA DA 11 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Centers for AIDS Research and Developmental Centers for AIDS Research (P30) Apply for PAR 11 108 Funding Number: PAR 11 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 11 074", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.